Structured evidence table for Urolithin A Muscle Endurance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Urolithin A Muscle Endurance Randomized Trial | Background Urolithin A (UA), a gut microbiota-derived metabolite, has been proposed to improve skeletal muscle function, but evidence from randomized controlled trials has not been systematically summarized. | 2 | Dao T (2026) | Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. |
| Urolithin A Muscle Endurance Randomized Trial | Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, and the certainty of evidence for the primary quantitatively synthesized outcome was rated using the GRADE approach. | 2 | Dao T (2026) | Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. |
| Urolithin A Muscle Endurance Randomized Trial | Conclusion The currently available randomized human evidence is limited to five small, short-term trials in clinically heterogeneous populations. | 2 | Dao T (2026) | Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. |
| Urolithin A Muscle Endurance Randomized Trial | This systematic review and meta-analysis aimed to evaluate the effects of UA supplementation on muscle performance as well as biochemical and mitochondrial biomarkers in humans. | 2 | Dao T (2026) | Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. |
Source documents